What is Generate Biomedicines, Inc. 's G&A?

Generate Biomedicines, Inc. (GENB) reported G&A of $13.52M in Q1 2026.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Generate Biomedicines, Inc. GENB G&A

G&A at other companies

SSR MiningSSRM

$38.48M+61.0%

NNN REITNNN

$14.11M+8.4%

IPG PhotonicsIPGP

$36.09M+10.0%

QuantumScape Corporation QS

$24.61M-12.1%

Global Business Travel GroupGBTG

$98M+44.1%

Generate Biomedicines, Inc. GENB

$13.52M+33.3%

Other financials

Income statement

See full

Revenue$7.2M-18.1%

Operating income-$64.1M-33.1%

Net income-$61.4M-47.4%

EPS (diluted)-$1.07+34.0%

Balance sheet

See full

Cash & equivalents$160.6M-27.2%

Total debt$65.6M—

Total equity$514.8M+209%

Total assets$625.7M—

Cash flow

See full

Operating cash flow-$80.4M-51.2%

CapEx$3.8M+403%

Free cash flow-$84.2M-56.1%

Valuation

See full

Market cap$1.86B—

Enterprise value$1.76B—

Returns & leverage

See full

Debt / equity0.1×—

Current ratio9.2×—

Where this comes from

Reported directly by Generate Biomedicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Generate Biomedicines, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Generate Biomedicines, Inc. 's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Generate Biomedicines, Inc. 's G&A?: Generate Biomedicines, Inc. (GENB) reported G&A of $13.52M in Q1 2026.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.